Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
Ohio State, Arthur G. James Cancer Hospital
mi
from
Columbus, OH
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
Ohio State, Arthur G. James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
Medical University of South Carolina
mi
from
Charleston, SC
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
Virginia Commonwealth University, Medical College of Virginia (MCV) Hospital
mi
from
Richmond, VA
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
Virginia Commonwealth University, Medical College of Virginia (MCV) Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated:  9/27/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)
Status: Enrolling
Updated: 9/27/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  9/27/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 9/27/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Gut Microbiome and Colorectal Tumors
The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer
Status: Enrolling
Updated:  9/28/2017
New York University School of Medicine
mi
from
New York, NY
Study of Gut Microbiome and Colorectal Tumors
The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer
Status: Enrolling
Updated: 9/28/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Yale Comprehensive Cancer Center
mi
from
New Haven, CT
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Yale Comprehensive Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Rush University Medical Center
mi
from
Chicago, IL
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Decatur Memorial Hospital
mi
from
Decatur, IL
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
University of Kansas Cancer Center and Medical Pavilion
mi
from
Westwood, KA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
University of Kansas Cancer Center and Medical Pavilion
mi
from
Westwood, KA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
University of Kentucky
mi
from
Lexington, KY
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Norton Cancer Institute
mi
from
Louisville, KY
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Tufts Medical Center
mi
from
Boston, MA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Mount Sinai Hospital
mi
from
New York, NY
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
NY Presbyterian - Weill Cornell Medical Center
mi
from
New York, NY
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
NY Presbyterian - Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Levine Cancer Institute
mi
from
Charlotte, NC
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Duke Cancer Center
mi
from
Durham, NC
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Cleveland Clinic
mi
from
Cleveland, OH
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Cancer Care Northwest
mi
from
Spokane Valley, WA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Cancer Care Northwest
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
City of Hope
mi
from
Duarte, CA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
University of Colorado
mi
from
Aurora, CO
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Northwestern University
mi
from
Chicago, IL
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Institut Jules Bordet
mi
from
Bruxelles,
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Institut Jules Bordet
mi
from
Bruxelles,
Click here to add this to my saved trials
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated:  9/29/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status: Enrolling
Updated: 9/29/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Status: Enrolling
Updated:  9/29/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Status: Enrolling
Updated: 9/29/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)
Status: Enrolling
Updated:  10/2/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)
Status: Enrolling
Updated: 10/2/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies
Status: Enrolling
Updated:  10/4/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies
Status: Enrolling
Updated: 10/4/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated:  10/5/2017
Rho, Inc.
mi
from
Chapel Hill, NC
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated: 10/5/2017
Rho, Inc.
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated:  10/5/2017
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated: 10/5/2017
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated:  10/5/2017
Skåne University Hospital
mi
from
Malmö,
The Von Willebrand Disease (VWD) International Prophylaxis Study
The VWD International Prophylaxis (VIP) Study
Status: Enrolling
Updated: 10/5/2017
Skåne University Hospital
mi
from
Malmö,
Click here to add this to my saved trials
Probiotic Ingestion and Isoagglutinin Titers
Probiotic Ingestion and Isoagglutinin Titers
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Probiotic Ingestion and Isoagglutinin Titers
Probiotic Ingestion and Isoagglutinin Titers
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials